
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia...
AnemiaThis is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged >18 years who are receiving palliative chemotherapy and who are suffering from chemotherapy associated anemia. A standard treatment group (ERYPO®) will be included to provide a reference reflecting current standard medical practice.

A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis...
AnemiaThis single arm study will assess the efficacy and safety of subcutaneous methoxy polyethylene glycol-epoetin beta (Mircera) for the correction and maintenance of hemoglobin levels in predialysis patients with renal anemia who are not currently treated with erythropoietin stimulating agents (ESA). Eligible patients will receive monthly subcutaneous injections of Mircera at an initial recommended dose of 1.2 micrograms/kg. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants...
Renal AnemiaThis sequential study will assess the efficacy and safety of multiple doses of intravenous (IV) methoxy polyethylene glycol-epoetin beta (MIRCERA), and will determine the optimum starting dose for maintenance treatment of anemia in children with chronic kidney disease on hemodialysis. Pediatric participants will remain on epoetin alfa, epoetin beta or darbepoetin alfa during the screening period, after which they will receive IV MIRCERA monthly, at a starting dose related to the previous weekly epoetin or darbepoetin alfa dose. Depending on the response achieved, another group may be selected to receive a higher or a lower dose.

Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
AnemiaThe objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron...
AnemiaThe objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency...
AnemiaThe objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.

Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving...
AnemiaChronic Renal Failure1 moreThe purpose of this study is to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease who are on dialysis and are not taking any treatment to increase their red blood cell production.

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney...
AnemiaThe study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients with chronic kidney disease who are not on dialysis.

Peginesatide for Anemia in Chronic Hemodialysis Patients
AnemiaChronic Kidney Disease1 moreThe purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.

Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis...
AnemiaThis is a open-label, prospective study comparing intravenous (IV) iron supplementation to standard care in anemic patents undergoing peritoneal dialysis.